Role of CD4+CD25+ T regulatory cells in IL-2-induced vascular leak

International Immunology

Volumn 18, Issue 10, 2006, Pages 1461-1471

  Melencio, Louise ^a   McKallip, Robert J ^a   Guan, Hongbing ^a   Ramakrishnan, Rupal ^a   Jain, Reena ^b   Nagarkatti, Prakash S ^a   Nagarkatti, Mitzi ^a  

^a UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

IL 2; T regulatory cells; Th1 Th2 cytokines; Vascular leak

Indexed keywords

CD3 ANTIBODY; CD3 ANTIGEN; CD4 ANTIGEN; CD69 ANTIGEN; CD8 ANTIGEN; CELL SURFACE MARKER; DX5 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 12P40; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN; RANTES; RECOMBINANT INTERLEUKIN 2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAPILLARY LEAK SYNDROME; CD4+ CD25+ T LYMPHOCYTE; CELL DAMAGE; CELL MEDIATED CYTOTOXICITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE PREDISPOSITION; EFFECTOR CELL; ENDOTHELIUM CELL; FEMALE; FLOW CYTOMETRY; IMMUNOREGULATION; LYMPHOCYTE COUNT; LYMPHOCYTE DEPLETION; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REGULATORY T LYMPHOCYTE; SPLEEN CELL; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH2 CELL;

ANIMALS; AUTOIMMUNITY; CAPILLARY PERMEABILITY; CELLS, CULTURED; ENDOTHELIAL CELLS; FEMALE; IMMUNITY, CELLULAR; INTERLEUKIN-2; MICE; MICE, INBRED BALB C; SPECIES SPECIFICITY; SYNDROME; T-LYMPHOCYTES, REGULATORY; TH1 CELLS; TH2 CELLS; VASCULAR DISEASES;

EID: 33749013823     PISSN: 09538178     EISSN: 14602377     Source Type: Journal    
DOI: 10.1093/intimm/dxl079     Document Type: Article

References (53)

1. Baluna, R. and Vitetta, E. S. 1997. Vascular leak syndrome: A side effect of immunotherapy. Immunopharmacology 37:117.
2. Doherty, P. C., Allan, J. E., Lynch, F. and Ceredig, R. 1990. Dissection of an inflammatory process induced by CD8+ T cells. Immunol. Today 11:55.
3. Hewicker, M. and Trautwein, G. 1987. Sequential study of vasculitis in MRL mice. Lab. Anim. 21:335.
4. McCluskey, R. T. and Fienberg, R. 1983. Vasculitis in primary vasculitides, granulomatoses, and connective tissue diseases. Hum. Pathol. 14:305.
5. Moyer, C. F. and Reinisch, C. L. 1984. The role of vascular smooth muscle cells in experimental autoimmune vasculitis. I. The initiation of delayed type hypersensitivity angiitis. Am. J. Pathol. 117:380.
6. Tsukada, N., Matsuda, M., Miyagi, K. and Yanagisawa, N. 1993. Cytotoxicity of T cells for cerebral endothelium in multiple sclerosis. J. Neurol. Sci. 117:140.
7. Fyfe, G., Fisher, R. I., Rosenberg, S. A., Sznol, M., Parkinson, D. R. and Louie, A. C. 1995. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J. Clin. Oncol. 13:688.
8. Rosenberg, S. A., Lotze, M. T., Muul, L. M. et al. 1985. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N. Engl. J. Med. 313:1485.
9. Rosenberg, S. A., Mule, J. J., Spiess, P. J., Reichert, C. M. and Schwarz, S. L. 1985. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J. Exp. Med. 161:1169.
10. Jacobson, E. L., Pilaro, F. and Smith, K. A. 1996. Rational interleukin 2 therapy for HIV positive individuals: Daily low doses enhance immune function without toxicity. Proc. Natl Acad. Sci. USA 93:10405.
11. Bechard, D. E., Gudas, S. A., Sholley, M. M. et al. 1989. Nonspecific cytotoxicity of recombinant interleukin-2 activated lymphocytes. Am. J. Med. Sci. 298:28.
12. Vial, T. and Descotes, J. 1995. Clinical toxicity of cytokines used as haemopoietic growth factors. Drug Saf. 13:371.
13. Nakajima, T., Schulte, S., Warrington, K. J. et al. 2002. T-cell-mediated lysis of endothelial cells in acute coronary syndromes. Circulation 105:570.
14. Rafi, A. Q., Zeytun, A., Bradley, M. J. et al. 1998. Evidence for the involvement of Fas ligand and perforin in the induction of vascular leak syndrome. J. Immunol. 161:3077.
15. Rafi-Janajreh, A. Q., Chen, D., Schmits, R. et al. 1999. Evidence for the involvement of CD44 in endothelial cell injury and induction of vascular leak syndrome by IL-2. J. Immunol. 163:1619.
16. Yoneda, O., Imai, T., Goda, S. et al. 2000. Fractalkine-mediated endothelial cell injury by NK cells. J. Immunol. 164:4055.
17. McKallip, R. J., Fisher, M., Do, Y. et al. 2003. Targeted deletion of CD44v7 exon leads to decreased endothelial cell injury but not tumor cell killing mediated by IL-2 activated cytolytic lymphocytes. J. Biol. Chem. 44:43818.
18. Scheffold, A., Huhn, J. and Hofer, T. 2005. Regulation of CD4(+)CD25(+) regulatory T cell activity: It takes (IL-)two to tango. Eur. J. Immunol. 35:1336.
19. Lindley, S., Dayan, C. M., Bishop, A., Roep, B. O., Peakman, M. and Tree, T. I. 2005. Defective suppressor function in CD4(+)CD25(+) T-cells from patients with type 1 diabetes. Diabetes 54:92.
20. Eggena, M. P., Barugahare, B., Jones, N. et al. 2005. Depletion of regulatory T cells in HIV infection is associated with immune activation. J. Immunol. 174:4407.
21. Balandina, A., Lecart, S., Dartevelle, P., Saoudi, A. and Berrih-Aknin, S. 2005. Functional defect of regulatory CD4(+)CD25+ T cells in the thymus of patients with autoimmune myasthenia gravis. Blood 105:735.
22. Thornton, A. M. and Shevach, E. M. 1998. CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J. Exp. Med. 188:287.
23. Shevach, E. M., McHugh, R. S., Piccirillo, C. A. and Thornton, A. M. 2001. Control of T-cell activation by CD4+ CD25+ suppressor T cells. Immunol. Rev. 182:58.
24. Earle, K. E., Tang, Q., Zhou, X. et al. 2005. In vitro expanded human CD4+CD25+ regulatory T cells suppress effector T cell proliferation. Clin. Immunol. 115:3.
25. Cosmi, L., Liotta, F., Angeli, R. et al. 2004. Th2 cells are less susceptible than Th1 cells to the suppressive activity of CD25+ regulatory thymocytes because of their responsiveness to different cytokines. Blood 103:3117.
26. Kidd, P. 2003. Th1/Th2 balance: The hypothesis, its limitations, and implications for health and disease. Altern. Med. Rev. 8:223.
27. Leipner, C., Grun, K., Schneider, I., Gluck, B., Sigusch, H. H. and Stelzner, A. 2004. Coxsackievirus B3-induced myocarditis: Differences in the immune response of C57BL/6 and Balb/c mice. Med. Microbiol. Immunol. (Berl) 193:141.
28. Ulett, G. C., Ketheesan, N. and Hirst, R. G. 2000. Cytokine gene expression in innately susceptible BALB/c mice and relatively resistant C57BL/6 mice during infection with virulent Burkholderia pseudomallei. Infect. Immun. 68:2034.
29. Biedermann, T., Zimmermann, S., Himmelrich, H. et al. 2001. IL-4 instructs TH1 responses and resistance to Leishmania major in susceptible BALB/c mice. Nat. Immunol. 2:1054.
30. Udaka, K. 1970. Simple method for quantification of enhanced vascular permeability. Proc. Soc. Exp. Biol. Med. 133:1384.
31. Mustafa, A., McKallip, R. J., Fisher, M., Duncan, R., Nagarkatti, P. S. and Nagarkatti, M. 2002. Regulation of interleukin-2-induced vascular leak syndrome by targeting CD44 using hyaluronic acid and anti-CD44 antibodies. J. Immunother. 25:476.
32. Li, L., Elliott, J. F. and Mosmann, T. R. 1994. IL-10 inhibits cytokine production, vascular leakage, and swelling during T helper 1 cell-induced delayed-type hypersensitivity. J. Immunol. 153:3967.
33. McKee, A. S. and Pearce, E. J. 2004. CD25+CD4+ cells contribute to Th2 polarization during helminth infection by suppressing Th1 response development. J. Immunol. 173:1224.
34. Assier, E., Jullien, V., Lefort, J. et al. 2004. NK cells and polymorphonuclear neutrophils are both critical for IL-2-induced pulmonary vascular leak syndrome. J. Immunol. 172:7661.
35. Wahl, S. M., Vazquez, N. and Chen, W. 2004. Regulatory T cells and transcription factors: Gatekeepers in allergic inflammation. Curr. Opin. Immunol. 16:768.
36. Dorner, B. G., Scheffold, A., Rolph, M. S. et al. 2002. MIP-1alpha, MIP-1beta, RANTES, and ATAC/lymphotactin function together with IFN-gamma as type 1 cytokines. Proc. Natl Acad. Sci. USA 99:6181.
37. Karlsson Faresjo, M. G. and Ludvigsson, J. 2005. Diminished Th1-like response to autoantigens in children with a high risk of developing type 1 diabetes. Scand. J. Immunol. 61:173.
38. Ohmura, K., Nguyen, L. T., Locksley, R. M., Mathis, D. and Benoist, C. 2005. Interleukin-4 can be a key positive regulator of inflammatory arthritis. Arthritis Rheum. 52:1866.
39. Sospedra, M. and Martin, R. 2005. Immunology of multiple sclerosis. Annu. Rev. Immunol. 23:683.
40. Kusuda, T., Shigemasa, K., Arihiro, K., Fujii, T., Nagai, N. and Ohama, K. 2005. Relative expression levels of Th1 and Th2 cytokine mRNA are independent prognostic factors in patients with ovarian cancer. Oncol. Rep. 13:1153.
41. Fontenot, J. D. and Rudensky, A. Y. 2005. A well adapted regulatory contrivance: Regulatory T cell development and the forkhead family transcription factor Foxp3. Nat. Immunol. 6:331.
42. Paust, S. and Cantor, H. 2005. Regulatory T cells and autoimmune disease. Immunol. Rev. 204:195.
43. Thornton, A. M. and Shevach, E. M. 2000. Suppressor effector function of CD4+CD25+ immunoregulatory T cells is antigen non-specific. J. Immunol. 164:183.
44. Kuhn, R., Lohler, J., Rennick, D., Rajewsky, K. and Muller, W. 1993. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 75:263.
45. Maloy, K. J., Salaun, L., Cahill, R., Dougan, G., Saunders, N. J. and Powrie, F. 2003. CD4+CD25+ T(R) cells suppress innate immune pathology through cytokine-dependent mechanisms. J. Exp. Med. 197:111.
46. Nakamura, K., Kitani, A., Fuss, I. et al. 2004. TGF-beta 1 plays an important role in the mechanism of CD4+CD25+ regulatory T cell activity in both humans and mice. J. Immunol. 172:834.
47. Golgher, D., Jones, E., Powrie, F., Elliott, T. and Gallimore, A. 2002. Depletion of CD25+ regulatory cells uncovers immune responses to shared murine tumor rejection antigens. Eur. J. Immunol. 32: 3267.
48. Onizuka, S., Tawara, I., Shimizu, J., Sakaguchi, S., Fujita, T. and Nakayama, E. 1999. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res. 59:3128.
49. Shimizu, J., Yamazaki, S. and Sakaguchi, S. 1999. Induction of tumor immunity by removing CD25+CD4+ T cells: A common basis between tumor immunity and autoimmunity. J. Immunol. 163:5211.
50. Nagai, H., Horikawa, T., Hara, I. et al. 2004. In vivo elimination of CD25+ regulatory T cells leads to tumor rejection of B16F10 melanoma, when combined with interleukin-12 gene transfer. Exp. Dermatol. 13:613.
51. Javia, L. R. and Rosenberg, S. A. 2003. CD4+CD25+ suppressor lymphocytes in the circulation of patients immunized against melanoma antigens. J. Immunother. 26:85.
52. Viguier, M., Lemaitre, F., Verola, O. et al. 2004. Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J. Immunol. 173:1444.
53. Quan, W. D., Jr, Khan, N., Ramirez, M. et al. 2005. Correlation between development of pulmonary edema and response of pulmonary metastases of metastatic melanoma and kidney cancer to high-dose continuous-infusion interleukin-2. Cancer Biother. Radiopharm. 20:151.